Compile Data Set for Download or QSAR
Report error Found 8 Enz. Inhib. hit(s) for PDB: 6RAV
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataKd:  7.90nMAssay Description:Binding affinity to human serine protease factor B by SPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor B [470-764](Human)
Hansoh Bio

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataKd:  9.93nMAssay Description:Table 2: Biacore 8 k instrument was primed using 1× PBS-P+ buffer before docking a Cytiva NTA chip. Recombinant human Factor B catalytic domain were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/12/2025
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 10nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 12nMAssay Description:Inhibition of human serine protease factor B by TR-FRET based competition binding assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 130nMAssay Description:Inhibition of serine protease factor B in 50% human whole blood assessed as reduction in alternative pathway-mediated membrane attack complex formati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 400nMAssay Description:Inhibition of human serine protease factor B in human PNH patient derived sample assessed as prevention of erythrocyte lysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/12/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 1.10E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/22/2019
Entry Details
US Patent
PDB3D3D Structure (crystal)